about
Development of Human Membrane Transporters: Drug Disposition and PharmacogeneticsPharmGKB: the Pharmacogenomics Knowledge Base.ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children.Pharmacogenomic considerations in opioid analgesia.Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.Neonatal withdrawal syndrome due to maternal codeine usePharmacogenetics: Using Genetic Information to Guide Drug Therapy.Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.ABCC3 genetic variants are associated with postoperative morphine-induced respiratory depression and morphine pharmacokinetics in children.Pharmacogenetic testing: Current Evidence of Clinical Utility.Personalized therapy in pain management: where do we stand?The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients.The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects.Pharmacogenetics: a general review on progress to date.Codeine in mothers and children: where are we now?A validated method for simultaneous determination of codeine, codeine-6-glucuronide, norcodeine, morphine, morphine-3-glucuronide and morphine-6-glucuronide in post-mortem blood, vitreous fluid, muscle, fat and brain tissue by LC-MS.A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events.Proteomic Analysis of the Developmental Trajectory of Human Hepatic Membrane Transporter Proteins in the First Three Months of Life.CYP2D6 phenotype-specific codeine population pharmacokinetics.
P2860
Q26786582-11AB800F-12F3-411F-87C6-40CBE4465E76Q33855594-5ABF0D8F-7131-4111-946A-BEAAE5FDA88DQ34308014-562562AC-37FB-4E23-928A-94486BC58CABQ34316700-2953328F-A8EF-499E-98CC-B480C63984C2Q34399802-E801F9E4-36E5-49F4-968C-635CF82164B7Q36054856-9D52A049-7ADB-4021-AB6D-42FD7EDA7470Q36508972-780E31F2-4481-4BDD-BC92-9C44C3308FA8Q37047429-261B379B-1D9F-4042-8CBD-8283E6FECE04Q37124058-EF7471C1-4355-4695-8746-6022BBF4263BQ37151528-79B42F9A-F1A7-4340-8F87-CBCF7DEC933EQ37760955-5FE048F1-F368-4C08-A926-EBC7FEF607C6Q38844220-12CF3476-4DEA-4C0D-A7AD-8B79C519FDA2Q39219864-49446AC1-99A7-431F-B184-AE46AD5498E4Q47776901-D2FC4A9F-1A92-45DE-B88E-718E6D09BBD5Q47875574-7CB8BFFD-291A-429E-95A7-35DD1B73B6A1Q48392462-00CCA112-AAA1-435D-A402-F177CE8A15C4Q50432917-D49010E9-70A2-4F01-84C6-7CCD99796ED1Q50518550-4F8BF567-558D-487B-AE77-AE5E06E69D44Q53644957-5FADE95C-F8C8-44B5-967F-A1B59BACC658
P2860
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Codeine and morphine pathway.
@en
Codeine and morphine pathway.
@nl
type
label
Codeine and morphine pathway.
@en
Codeine and morphine pathway.
@nl
prefLabel
Codeine and morphine pathway.
@en
Codeine and morphine pathway.
@nl
P1476
Codeine and morphine pathway.
@en
P2093
Caroline F Thorn
Teri E Klein
P304
P356
10.1097/FPC.0B013E32832E0EAC
P50
P577
2009-07-01T00:00:00Z